Biodel to file VIAject insulin for diabetes
This article was originally published in Scrip
Biodel has announced plans to submit an NDA to the US FDA for its lead product, an ultra-rapid-acting injectable human insulin, VIAject, to treat type 1 and type 2 diabetes, in the second half of this year.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.